Key result
17β-estradiol reduces ventricular sarcomere shortening amplitude by ~24% while sparing atrial contractility.
Why the study?
Previous studies have reported 17beta-estradiol effects predominantly on ventricles, while its impact on atria has been less examined.
Does 17β-estradiol affect the contractile function of atrial and ventricular cardiomyocytes differently in female rats?
Does 17β-estradiol affect the contractile function of atrial and ventricular cardiomyocytes differently in female rats?
17β-estradiol impairs the mechanical function of ventricular myocardium while preserving atrial contractility, highlighting chamber-specific sensitivity that may be relevant for understanding the cardiac effects of hormonal replacement therapy.
17β-estradiol (E2) is the most active metabolite of estrogen with a wide range of physiological action on cardiac muscle. Previous studies have reported E2 effects predominantly for the ventricles, while the E2 impact on the atria has been less examined. In this study, we focused on the direct E2 effects on atrial and ventricular contractility at the cellular and molecular levels. Single atrial and ventricular cardiomyocytes (CM) from adult (24 weeks-old) female Wistar rats were incubated with 10 nM E2 for 15 min. Sarcomere length and cytosolic [Ca2+]i transients were measured in mechanically non-loaded CM, and the tension–length relationship was studied in CM mechanically loaded by carbon fibers. The actin–myosin interaction and sarcomeric protein phosphorylation were analyzed using an in vitro motility assay and gel electrophoresis with Pro-Q Diamond phosphoprotein stain. E2 had chamber-specific effects on the contractile function of CM with a pronounced influence on ventricular CM. The characteristics of [Ca2+]i transients did not change in both atrial and ventricular CM. However, in ventricular CM, E2 reduced the amplitude and maximum velocity of sarcomere shortening and decreased the slope of the passive tension–length relationship that was associated with increased TnI and cMyBP-C phosphorylation. E2 treatment accelerated the cross-bridge cycle of both atrial and ventricular myosin that was associated with increased phosphorylation of the myosin essential light chain. This study shows that E2 impairs the mechanical function of the ventricular myocardium while atrial contractility remains mostly preserved. Hormonal replacement therapy (HRT) with estrogen is by far the most effective therapy for treating climacteric symptoms experienced during menopause. Here we found a chamber specificity of myocardial contractile function to E2 that should be taken into account for the potential side effects of HRT.
No takes yet. Share an insight, caveat, or question.
Myachina et al. (2025) studied Healthy (animal model). 17β-estradiol (E2) vs. Vehicle control (ethanol) was evaluated on Fractional and absolute sarcomere shortening amplitude in ventricular cardiomyocytes (24% reduction, p=<0.05). In ventricular cardiomyocytes, 10 nM 17β-estradiol reduced the amplitude of sarcomere shortening by approximately 24% and maximum velocity by 12%, while atrial contractility was mostly preserved.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: